RxDoctor Payments Data

Cynthia Wade, APRN

Nurse Practitioner · Fort Worth, TXNPI 1205356045

Payments from drug & device makers

$4,493in general payments, 2019–2025

Across 268 payments — averaging $16.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$613
  • QOL Medical, LLC$298
  • Johnson & Johnson$281
  • Intercept Pharmaceuticals, Inc.$212
  • Bristol Myers Squibb$210
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,41298%
  • Education$812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,493 in reported general payments places this provider in the 90th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$40,605
Medicare patients
266
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab28$203,423
ZenpepLipase/Protease/Amylase31$107,349
CreonLipase/Protease/Amylase32$79,123
XifaxanRifaximin24$66,938
LinzessLinaclotide30$27,233
Mesalamine36$17,558
PentasaMesalamine12$14,167
Budesonide DrBudesonide24$6,445
Pantoprazole Sodium377$5,445
Famotidine207$3,401
Sucralfate58$2,492
Budesonide EcBudesonide12$2,398
Omeprazole126$2,378
Esomeprazole Magnesium34$1,758
Dicyclomine Hcl55$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$120$107,34931 claims
AbbVieCreon, Linzess$1,686$106,35662 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$613$66,93824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →